PRESTO 2: An international patient survey to evaluate impact of injection and delivery system on local pain when administering somatostatin analogue (SSA) therapy

#3515

Introduction: Long-acting (LA) SSA therapy is a common long-term treatment for NETs, but real-world data on patients’ injection experience using the latest LA SSA designs/formulations are limited.

Aim(s): The primary aim of PRESTO 2 was to compare pain at injection site lasting >2 days after lanreotide autogel/depot (LAN) prefilled syringe vs octreotide LA release syringe (OCT).

Materials and methods: An e-survey (conducted in 2021) of adults with NETs or acromegaly from Canada, USA, UK and Ireland, who had received ≥3 months’ treatment with LAN or OCT (planned sample size, 304). Primary endpoint: Proportion of patients with injection-site pain lasting >2 days after last injection, analysed using multivariate logistic regression model. Secondary endpoint: Interference with daily life as a result of injection-site pain.

Conference:

Presenting Author: O'Toole D

Authors: O'Toole D, Prebtani A, Webb S, Houchard A, Gueguen D,

Keywords: acromegaly, injection site pain, lanreotide autogel/depot, neuroendocrine tumor, octreotide long-acting release syringe, patient survey,